BioSpace News Archive

Oculis has identified pressing unmet therapeutic needs and innovative, differentiated approaches to meet those needs.

JW Therapeutics, an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation of the National Medical Products Administration of China granted Breakthrough Therapy Designation for Carteyva® in patients with mantle cell lymphoma.

Ascletis Pharma Inc. announces that it has submitted the marketing authorization application for ritonavir in the Hong Kong Special Administrative Region of the People’s Republic of China.

Silence Therapeutics plc presented detailed results from its phase 1 APOLLO trial that showed SLN360, an investigational siRNA, reduced levels of lipoprotein ”), an important genetic risk factor for heart disease, by up to 98% in healthy adults with high Lp.

BridgeBio Pharma, Inc. announced updated data from its ongoing Phase 2 open-label extension study of acoramidis in patients with symptomatic transthyretin amyloid cardiomyopathy.

Cytokinetics, Incorporated announced that the full results from METEORIC-HF, a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, were presented by Michael Felker, M.D., Professor of Medicine, Duke Clinical Research Institute, at the American College of Cardiology 71st Annual Scientific Session.

CanSino Biologics Inc. announced that the National Medical Products Administration of China granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced two poster presentations at the American Association for Cancer Research Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers.

Shanghai Junshi Biosciences Co., Ltd announced that the U.S. Food and Drug Administration has approved its Investigational New Drug application for its anti-CD112R monoclonal antibody for the treatment of advanced solid tumors.

Bristol Myers Squibb announced new, interim results from the EXPLORER-LTE cohort of the MAVA-LTE study, the largest and longest evaluation of mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with symptomatic obstructive hypertrophic cardiomyopathy.